The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
Golebiowski, A., Townes, J.A., Laufersweiler, M.J., Brugel, T.A., Clark, M.P., Clark, C.M., Djung, J.F., Laughlin, S.K., Sabat, M.P., Bookland, R.G., Vanrens, J.C., De, B., Hsieh, L.C., Janusz, M.J., Walter, R.L., Webster, M.E., Mekel, M.J.(2005) Bioorg Med Chem Lett 15: 2285-2289
- PubMed: 15837310 
- DOI: https://doi.org/10.1016/j.bmcl.2005.03.007
- Primary Citation of Related Structures:  
1YWR - PubMed Abstract: 
4-Aryl-5-pyrimidyl based cytokine synthesis inhibitors that contain a novel monocyclic, pyrazolone heterocyclic core are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-alpha production. One of the compounds (6e) was found to be efficacious in the rat iodoacetate (RIA) in vivo model of osteoarthritis. The X-ray crystal structure of a pyrazolone inhibitor cocrystallized with mutated p38 (mp38) is presented.
Organizational Affiliation: 
Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd, Mason, OH 45040, USA. golebiowski.a@pg.com